Internal Medicine, Hematology & Oncology · Aurora, CO
NPI
1184817959
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
12605 E 16th Ave
Aurora, CO, 80045
Phone (720) 848-0000
Groups this clinician bills Medicare through
Medicare paid, 2024
$45K
517 services
Medicare patients, 2024
244
Average age 73
Drug cost, 2024
$4.3M
641 prescriptions
Company payments, 2025
$46K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Manali K Kamdar was code 99214 (office e&m - established), 244 times for 167 patients. In total Manali K Kamdar billed 517 services in 7 codes, and Medicare paid $45K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-12-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 244 | 167 | $67.16 | $16K |
| 99233 Hospital E&M - Subsequent | Facility | 129 | 25 | $93.17 | $12K |
| 99215 Office E&M - Established | Facility | 74 | 62 | $111.14 | $8,224 |
| 99205 Office E&M - New | Facility | 30 | 30 | $138.37 | $4,151 |
| 99215 Office E&M - Established | Office | 19 | 16 | $131.20 | $2,493 |
| 99214 Office E&M - Established | Office | 14 | 12 | $94.01 | $1,316 |
By year: 2022 $41K for 521 services; 2023 $38K for 454 services; 2024 $45K for 517 services.
Medicare prescription drug claims, 2024
In 2024, the drug Manali K Kamdar prescribed most often to Medicare patients was Calquence (Acalabrutinib Maleate), with 172 prescriptions and refills. In total Manali K Kamdar wrote 641 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calquence Acalabrutinib Maleate | 172 | 172 | 19 | $2.4M |
| Acyclovir Generic | 131 | 172 | 40 | $2,623 |
| Brukinsa Zanubrutinib | 38 | 38 | Under 11 | $555K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 31 | 35 | Under 11 | $114 |
| Jaypirca Pirtobrutinib | 23 | 23 | Under 11 | $456K |
| Levofloxacin Generic | 22 | 22 | 15 | $113 |
| Prochlorperazine Maleate Generic | 20 | 20 | 13 | $225 |
| Ondansetron Hcl Generic | 20 | 20 | 12 | $127 |
| Imbruvica Ibrutinib | 19 | 19 | Under 11 | $311K |
| Venclexta Venetoclax | 17 | 17 | Under 11 | $249K |
| Fluconazole Generic | 15 | 15 | Under 11 | $533 |
Brand drugs: 297 claims; generic drugs: 344 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Manali K Kamdar $46K ($44K in general payments such as food, travel and fees and $1,492 for research) from 12 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $27K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.